spacer
home > epc > spring 2003 > archiving edc data: further challenges for compliance
PUBLICATIONS
European Pharmaceutical Contractor

Archiving EDC Data: Further Challenges for Compliance

The last 15 years has seen a gradual yet inexorable growth in the adoption of electronic data capture (EDC) by both pharmaceutical and medical device industries. Estimates vary on the uptake rates with some references suggesting a figure between four and 15 per cent on a global scale (1). Undoubtedly the increase in the enterprise-wide adoption of systems has cemented the commitment of the industry to such technology. To date, the focus of attention has very much been on front-end trial set-up activities such as edit check and screen design rather than planning for end-of-life archiving.

However as the regulatory framework is becoming established, company polices and procedures towards archiving need to be developed. It is clear that many companies are proving slow to prepare for the regulatory challenge, with an independent survey indicating that only 50 per cent of responders were aware of specific US rules on electronic records (2). This article will examine several of the key factors concerning the archiving of EDC data and it seems appropriate to commence by revisiting the use of paper records.

The Established Model

The archiving of paper records is a well-defined and established model. Any move to EDC needs to successfully challenge this approach. Paper itself is a robust medium if treated correctly and testament to this fact is the collection of 12th Century documents held by the UK Public Records Office, amongst others. However the maintenance of paper records is subject to various risk factors such as environmental conditions (that is temperature and humidity), fire, flood and pest damage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

Banner of CRS on Samedan
spacer
By Neil Konopka, Head of Quality & Regulatory Compliance (International)
 
Neil Konopka is Head of Quality and Regulatory Compliance for the international region of Phase Forward Inc. He began his 16-year industry career in the biopharmaceutical manufacturing arena, but has since focused on clinical quality assurance, having previously held positions within Bayer and SmithKline Beecham. Neil graduated from the University of Surrey in 1986 with an honours degree in Medical Biochemistry.

He is a member of the UK-based Clinical Research-Computer Systems Validation (CR-CSV) working party that aims to promote validation awareness throughout the business sector. Neil joined Phase Forward in 2000 and currently has responsibility for the international quality function, which conducts internal auditing and sub-contractor assessments together with regulatory support for operations in Europe, Asia-Pacific and Japan.


spacer
Neil Konopka
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

BIO-Europe Spring® 2012 — 6th International Partnering Conference

19-21 March 2012, Amsterdam RAI Convention Center, Amsterdam, The Netherlands

BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.  
More info >>

 
News and Press Releases

Record sales of new de-blistering and leak testing equipment at packaging machinery manufacturer, Sepha Ltd

The packaging machinery manufacturer, Sepha Ltd, has reported record sales of its recently extended range of non-destructive leak testing equipment for the world's pharmaceutical packaging industry. With demand up across all major markets, the company says the increase will fund future R&D and enable it to bring forward future innovations aimed at reducing costs and driving quality for pharmaceutical manufacturers and contract packers.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.